G. Alonso

Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.

G. Curigliano, L. Paz-Ares, M. Schuler, 2021 .

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

P. LoRusso, E. Stanganello, U. Şahin, 2022, Cancer discovery.

Inhibitors of protein synthesis in eukarytic cells. Comparative effects of some amaryllidaceae alkaloids.

A. Santos, A. Jimenez, D. Vazquez, 1976, Biochimica et biophysica acta.

Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies

J. Tabernero, I. Baraibar, J. Ros, 2022, Expert opinion on investigational drugs.

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

A. Mansfield, R. Doebele, G. Curigliano, 2020, Journal of Clinical Oncology.

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors.

A. Mansfield, R. Doebele, G. Curigliano, 2020, Journal of Clinical Oncology.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

A. Drilon, Keunchil Park, B. Solomon, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).

A. Drilon, Keunchil Park, B. Solomon, 2021 .

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

T. Guren, E. Massarelli, C. Cremolini, 2023, Nature medicine.